The use of Atypical antipsychotics in French psychiatric hospitals
- 72 Downloads
To study the prescribing practices of atypical antipsychotic drugs in French psychiatric hospitals.
A 1-day cross-sectional observational survey was performed in seven psychiatric hospitals to study prescribing practices of the four atypical antipsychotics (AAP) marketed in France. These hospitals are members of the PIC network, a pharmacists’ working group based in southwestern France.
Main outcome measures
Type and dosages of prescribed atypical antipsychotics, indication and concomitant prescriptions.
The study included 1475 adult inpatients’ prescriptions with an antipsychotic drug; 647 prescriptions included an AAP with risperidone and olanzapine accounting for about 70% cases. AAP prescriptions concerned psychotic patients in 65% of cases. Patients receiving an AAP in this indication were more likely to be male, were younger, and received higher daily doses than patients treated for other troubles. They were also more likely to receive associated neuroleptic and anticholinergic antiparkinsonian agents. There were 59 prescriptions (9.1%) for bipolar disorders. Clozapine wasn’t used in this indication. In 76.3% of cases, mood stabilizers were associated to the AAP prescribed in this indication.
This observational survey underlines the significant place taken by AAP for the treatment of psychiatric diseases in hospital prescribing practices. They show usage patterns of these drugs: dose, indications and concomitant medications, in line or not with current recommendations and reference guidelines. In bipolar disorders, AAPs seem more likely to be associated to an ongoing therapy using mood stabilizer than to replace it.
KeywordsAtypical antipsychotics France Guidelines Hospital pharmacy Prescribing Psychiatry
Unable to display preview. Download preview PDF.
The authors would like to acknowledge all the participants who helped in data collection, and in particular, Dr Pierre Bret who performed the statistical analyses.
- 1.American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Am J Psych 1997;154(Suppl 4)Google Scholar
- 2.Andem (National Agency for Development of Medical Evaluation) Recommendations and medical references: neuroleptic prescriptions. Concours Medical 1997;119:1441–5, 1609–14, 1767–73Google Scholar
- 3.Augry F, Esvan M. Prescription of atypical antipsychotics in a psychiatric hospital. Nervure 2001;IV: 7–13Google Scholar
- 4.Bret P, Bonnet F, Bret MC, Jaffre A. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux): prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone. Encephale 2002;XXVIII:329–42Google Scholar
- 5.Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment and care management for schizophrenia. Encephale 2002;XXVIII: 129–38Google Scholar
- 6.Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 12)Google Scholar
- 7.College of Quebec Clinicians. Schizophrenia treatment [Guidelines : Treating Schizoprenia] (June 1999). (on http://www.cmq.org/uploadedfiles/lignestraitementsschizophrenieang99.pdf)
- 8.Consensus Conference (THE). Strategies for long-term therapy of patients with schizophrenia. French federation of psychiatry, national agency for the development of medical evaluation and national union of friends and families of psychiatric patients (eds), Paris, 13 et 14 January 1994, 32 ppGoogle Scholar
- 9.Fabre Almaric E. Psychotropic drug prescriptions and corrector agent prescriptions in a French psychiatric hospital. Pharmacie Hospitaliere Française 1998;124:69–77Google Scholar
- 11.Gury C, Berchot F, Fabre C, Surugue J, Welcomme N. Analysis of neuroleptics prescriptions in five specialized hospitals: comparison between hospital prescriptions and discharge prescriptions. L’information psychiatrique 2002;8:954–63Google Scholar
- 12.ICD 10/CIM 10. The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines. 10th revision. Masson, 1994Google Scholar
- 15.Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophren Res 1998;35:51–68CrossRefGoogle Scholar
- 16.McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline series: treatment of schizophrenia. J Clin Psychiatr 1999;60(suppl 11)Google Scholar
- 18.Rouillon F, Lachaux B, Fender P, Moreau Defarges T, Richard A, Chicoye A. Pharmaco-repidemiological study of risperidone prescription. La Lettre du Pharmacologue 2000;7:170–5Google Scholar
- 19.Taylor D, Mc Connell D, Mc Connell H, Abel K, Kervin R. The bethlem and maudsley NHS trust: prescribing guidelines., 5th ed., London: Martin Dunitz; 1999Google Scholar
- 20.Working Group for the Canadian Psychiatric Association and the Canadian alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(suppl. 2)Google Scholar